MSB ASX News

30 July 2024

Quarterly Activities/Appendix 4C Cash Flow Report

Mesoblast provides updates on FDA reviews and financial performance for Q4 2024.

Mesoblast FDA Approval Stock Market News Biotechnology Financial Performance

Posted on: 30/07/2024

23 July 2024

FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L

FDA accepts Mesoblast's BLA for Ryoncil in treating pediatric SR-aGVHD.

Mesoblast Ryoncil FDA Approval Biologics License Application Stock Market News

Posted on: 23/07/2024

8 July 2024

Mesoblast Resubmits BLA with FDA for Ryoncil Approval

Mesoblast resubmits BLA for Ryoncil to treat children with SR-aGVHD.

Mesoblast Ryoncil FDA Biologic License Application SR-aGVHD Stock Market News

Posted on: 08/07/2024